Evidence map›Paper›PMID 40764319›Full record

ArticleNPJ vaccines2025

Priming VRC01-precursor B cells with non-envelope immunogens disfavors boosting with HIV-1 envelope.

Andrew Wilcox-King, Yu-Hsin Wan, Samuel C Scharffenberger, Crystal B Chhan, Amelia R Davis, Leah J Homad, Emilie Seydoux, Kellie J MacPhee, Latha Kallur Siddaramaiah, Mariane Melo and 5 more

Abstract read
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Andrew Wilcox-KingVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Yu-Hsin WanVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Samuel C ScharffenbergerVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Crystal B ChhanVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Amelia R DavisVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Leah J HomadVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Emilie SeydouxVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Kellie J MacPheeVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Latha Kallur SiddaramaiahVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Mariane MeloKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Pia DosenovicDepartment of Microbiology, Tumor and Cell Biology, Division of Virology and Immunology, Karolinska Institutet, Solna, Sweden.
Darrell J IrvineKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Ollivier HyrienVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Leonidas StamatatosVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. lstamata@fredhutch.org.
Andrew T McGuireVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. amcguire@fredhutch.org.

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
Recombinant HIV-1 Env glycoprotein immunogens and antibodies production and structural characterizationP01AI138212 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STAMATATOS, LEONIDAS · 2019 to 2023
$9.2M
Gates Foundation INV-032929National Institute of Allergy and Infectious Diseases P01AI138212National Institute of Allergy and Infectious Diseases UM1AI144462NCI NIH HHS P30 CA015704NIAID NIH HHS P01 AI138212NIAID NIH HHS UM1 AI144462
6 · The paper itself

Abstract

VRC01-class antibodies are a genetically restricted class of antibodies capable of potently neutralizing diverse strains of HIV-1. Unmutated VRC01 precursors fail to recognize recombinant HIV-1 Envelope (Env) proteins, which necessitated the development of germline targeting vaccine immunogens capable of initiating VRC01-class B cell response. Among these, we developed an anti-idiotypic monoclonal antibody (ai-mAb)-derived VRC01 class targeting immunogen. Because it is distinct from Env, we speculated that the ai-mAb will selectively engage naive VRC01 class B cells while limiting B cell responses directed at off-target epitopes on Env during prime-boost regimens. Here, we evaluated the serum and B cell responses to ai-mAb prime/Env boost, and Env-prime/Env boost regimens in a murine adoptive transfer model where VRC01 precursor B cells are present at physiological levels. We found that the Env-Env regimen led to the greatest expansion of on-target VRC01 B cells, drove larger VRC01-class GC responses, and elicited higher titers of circulating antibodies despite also eliciting substantial off-target Env-specific responses. Single-cell sorting experiments revealed that the ai-mAb was driving off-track somatic mutations. IgG transfer experiments demonstrated that circulating off-target antibodies provide a positive feedback mechanism that potentiates on-target B cell responses. Collectively, the results suggest that non-Env immunogens are not ideal for priming VRC01-class B cells, where sequential boosting with Env will be required to drive maturation of neutralizing breadth.

Identifiers

PMID40764319
PMCPMC12325944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.